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Background
Osteoporosis and fracture risk are considered to be under genetic control. Extensive work is
being performed to identify the exact genetic variants that determine this risk. Previous work
has suggested that a G/T polymorphism affecting an Sp1 binding site in the COLIA1 gene is a
genetic marker for low bone mineral density (BMD) and osteoporotic fracture, but there have
been no very-large-scale studies of COLIA1 alleles in relation to these phenotypes.
Methods and Findings
Here we evaluated the role of COLIA1 Sp1 alleles as a predictor of BMD and fracture in a
multicenter study involving 20,786 individuals from several European countries. At the femoral
neck, the average (95% confidence interval [CI]) BMD values were 25 mg/cm2 (CI, 16 to 34 mg/
cm2) lower in TT homozygotes than the other genotype groups (p , 0.001), and a similar
difference was observed at the lumbar spine; 21 mg/cm2 (CI, 1 to 42 mg/cm2), (p ¼ 0.039).
These associations were unaltered after adjustment for potential confounding factors. There
was no association with fracture overall (odds ratio [OR] ¼ 1.01 [CI, 0.95 to 1.08]) in either
unadjusted or adjusted analyses, but there was a non-significant trend for association with
vertebral fracture and a nominally significant association with incident vertebral fractures in
females (OR¼ 1.33 [CI, 1.00 to 1.77]) that was independent of BMD, and unaltered in adjusted
analyses.
Conclusions
Allowing for the inevitable heterogeneity between participating teams, this study—which to
our knowledge is the largest ever performed in the field of osteoporosis genetics for a single
gene—demonstrates that the COLIA1 Sp1 polymorphism is associated with reduced BMD and
could predispose to incident vertebral fractures in women, independent of BMD. The
associations we observed were modest however, demonstrating the importance of conducting
studies that are adequately powered to detect and quantify the effects of common genetic
variants on complex diseases.
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Introduction
Osteoporosis is a common disease with a strong genetic
component, characterized by reduced bone mineral density
(BMD) and an increased risk of fragility fractures. A large
number of studies have been conducted on potential
associations between candidate gene polymorphisms and
various osteoporosis-related phenotypes, such as BMD,
quantitative ultrasound properties of bone, and risk of
fragility fractures [1]. Most of these studies were under-
powered to detect the modest effects that are expected for
genetic susceptibility to a complex disorder such as osteopo-
rosis [2]. Moreover, the results that have arisen from many
studies have not been replicated [3,4], or when large-scale
evidence has been obtained, results have been observed that
were different to those observed in initial studies [5]. The
COLIA1 gene, which encodes the alpha I chain of type 1
collagen, is one of the most extensively studied candidate
genes for susceptibility to osteoporosis. A single nucleotide
polymorphism affecting an Sp1 binding site within a key
regulatory region of COLIA1 [6] has previously been reported
to be associated with BMD and susceptibility to osteoporotic
fracture, particularly vertebral fractures [7–9]. Preclinical
studies have indicated that the COLIA1 Sp1 polymorphism is
a functional variant that affects collagen gene regulation and
bone quality [10,11]. In keeping with this, the association with
fracture in many clinical studies has been found to be
independent of BMD [7] and of greater magnitude than
would be expected from the reported genotype-speciﬁc
differences in BMD [8]. Although the data linking COLIA1
Sp1 genotype to osteoporosis is ostensibly convincing and has
been supported by meta-analyses [8,9,11], retrospective meta-
analysis may yield misleading results due to publication bias
or other confounding factors [12]. Given the potential
importance of the COLIA1 Sp1 polymorphism as a genetic
marker of osteoporosis outcomes on a population level, we
set out to generate large-scale evidence for these associations
in a collaborative study involving 26,242 individuals from
several European centers within the framework of the
Genetic Markers for Osteoporosis (GENOMOS) consortium.
Methods
Study Cohorts
The GENOMOS project is large-scale study of several
candidate gene polymorphisms in relation to osteoporosis-
related outcomes in individuals drawn from several European
centers [5].This report includes seven of the eight cohorts
that were included in a meta-analysis of ESR1 gene poly-
morphisms [5], with additional individuals from Austria
(Graz), Netherlands (Amsterdam), and Poland. One of the
previously studied cohorts (the Danish Osteoporosis Study)
was not included in this analysis because of potential coding
errors of some samples. Two of the participating teams
(Rotterdam and Barcelona) provided additional fracture data
on individuals who had been reported upon previously. For
three teams (the European Prospective Osteoporosis Study
[EPOS], Aarhus, and Florence), additional fracture and
genotype data were provided, and for one team (Aberdeen),
the fracture database was updated and validated further
compared with the previous GENOMOS analysis on estrogen
receptor alpha gene polymorphisms [5].
We refer to previous publications on the characteristics of
four longitudinal cohorts (the Rotterdam study [13], the
Aberdeen Prospective Osteoporosis Study (APOSS) [14], the
Longitudinal Aging Study Amsterdam (LASA) [15], and EPOS
[16]). Three cross-sectional studies of unrelated individuals
(Aarhus, Barcelona, and Florence) have previously been
described [5] as has a cross-sectional family-based study
(Familial Osteoporosis Study [FAMOS] run by the company
Oxagen) [17]. We also included data from two new
populations that were not part of our previous meta-analysis.
These are the cross-sectional European Polish Osteoporosis
Study [EPOLOS] study, which is a population-based study in
Poland recruiting men and women of continental European
ancestry aged 20–80 y with exclusion criteria of pregnancy,
cancer, obesity (weight .100 kg), and fractures occurring
during the year prior to enrolment. EPOLOS fracture cases
and age- and sex-matched controls were included and
analyzed as part of the EPOS cohort. Data were also included
from a study coordinated in Graz comprised of individuals
from a population-based study of normative ranges for BMD
in healthy men and women in Austria aged 21–76 y, as
described [18]. In addition, the Graz team collected data from
a study of elderly nursing homes residents (average age 84 y)
in Eastern Austria.
All participating teams contributed information on sex,
age, height, weight, COLIA1 Sp1 genotype, BMD at lumbar
spine and femoral neck (in mg/cm2), and (for women)
menopausal status and use of hormone replacement therapy.
All teams contributed information on fracture although this
information had been gathered differently by the participat-
ing centers. We originally assembled information as collected
by each team and then made efforts to standardize deﬁnitions
of fracture where possible.
Prevalent Fractures
In Aarhus, Rotterdam, and Barcelona, fractures that had
occurred at, or before the time of enrolment had been
validated by radiographic documentation. In Graz, Amster-
dam, Barcelona, EPOS, Florence, and Oxagen, fractures had
been ascertained on the basis of clinical history or ques-
tionnaire. All vertebral fractures had been documented by
radiographs with the exception of Aberdeen, where diagnosis
was based on questionnaire. In the Amsterdam, Florence, and
Oxagen cohorts, fractures occurring at any time of life were
counted; for Aberdeen, fractures occurring under age 18 y
were excluded; for EPOS and Graz, fractures occurring under
age 20 y were excluded; for Barcelona, fractures occurring
under age 45 y were excluded; whereas for Aarhus and
Rotterdam, only vertebral fractures documented radiograph-
ically at the time of enrolment were counted. Fractures of the
hands, ﬁngers, toes, feet, face, and skull were excluded in
Barcelona. In Graz, fractures of the hands, face, skull, and
clavicle were excluded. High-trauma fractures were excluded
upfront in Barcelona, EPOS, and Florence as part of the
original design of these studies.
Incident Fractures
For the longitudinal studies, data on incident fractures that
had occurred during the period of follow up were available,
and only fractures that could be validated by medical records,
scrutiny of original radiographs, or radiologist reports were
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included, except for EPOS where fractures were documented
by an interviewer-completed questionnaire. All incident
vertebral fractures were validated by radiographs.
Ethical Considerations
All participating centers have received institutional review
board and/or ethics committee approval according to their
local regulations, and informed consent has been obtained
according to the requirements of each center.
Genotyping
Genotyping for the COLIA1 Sp1 G to T polymorphism
(dbSNP rs1800012) was performed using various techniques,
including Taqman (EPOS, EPOLOS, Graz, and Rotterdam),
pyrosequencing (Oxagen), restriction fragment length poly-
morphism (RFLP) (Amsterdam and Barcelona), and DNA
sequencing (Aberdeen). Genotyping for the Florence and
Amsterdam cohorts was performed in Rotterdam, and
genotyping for the Aarhus cohort was performed in Aber-
deen. Standardization between centers was evaluated by
blinded genotyping of 50 randomly selected samples by all
centers. The results were evaluated by the coordinating
center in Rotterdam, and any discrepancies in the reference
plate were reported in order to improve calling of genotypes.
Genotyping of the reference plate was repeated again, and
centers had to switch genotyping techniques if they were still
generating more than 5% errors (more than two errors in 50)
in the reference plate (one center changed from RFLP to
Taqman). After this, full cohort genotypes were generated in
all centers. In addition, each center checked their own cohort
genotyping afterwards by re-genotyping at least 5% of their
samples with random selection, and fewer than 1% discrep-
ancies were observed for each cohort.
BMD Measurements
BMD was assessed by dual-energy X-ray absorptiometry
using Hologic bone densitometers (Hologic, Bedford, Massa-
chusetts, United States) in Aarhus, Amsterdam, Barcelona,
Florence, and Graz; Norland XR26 and XR36 densitometers
(Norland, Cooper Surgical, Trumbull, Connecticut, United
States) in Aberdeen; and a Lunar DPX-L or DPX densitometer
(Lunar, GE Medical Systems, Madison, Wisconsin, United
States) in Rotterdam and EPOLOS. For the multicenter EPOS
and FAMOS studies, a variety of devices were used and cross-
calibrated with the European Spine Phantom. Details of these
devices and the validation procedure for cross-calibration in
the FAMOS study have been described [19]. Syntheses of BMD
data across studies always include also a study effect that
would account both for genuine differences in populations
and potential systematic differences between these devices.
The results of the meta-analysis for BMD are interpreted with
emphasis on the BMD differences between the contrasted
genotypes and not on the absolute BMD values.
Outcomes
The main outcomes assessed were BMD of the lumbar spine
and femoral neck; all fractures (as deﬁned by each cohort);
and vertebral fractures as documented by clinical or
morphometric criteria [20]. To take account of differences
in methods of diagnosis and deﬁnition of fractures across
teams, we also performed sensitivity analyses using stand-
ardized criteria. These analyses were limited to incident
fractures; incident vertebral fractures; and low/no trauma
fractures (excluding fractures occurring with high trauma, as
assessed by the circumstances in which they had occurred
and/or their location). Information on low/no-trauma frac-
tures was available from all teams except Aberdeen and Graz.
For all analyses, data in each team were ﬁrst split according to
sex. In all studies, participants were unrelated with the
exception of the FAMOS study, of which we used only one
randomly selected person per pedigree for our analysis.
Sensitivity analysis using all FAMOS participants yielded
largely similar results (not shown).
Analyses
Analysis of variance (ANOVA) considered all possible
genotypes and used the study designation as random factor.
Adjusted analyses were also performed in which we included
age, height, weight, and (for women) hormone replacement
therapy and menopausal status as covariates. Estimated
marginal means in each genotype group were compared.
We estimated the unadjusted mean BMD and standard
deviation in each study for each genotype of interest. We then
synthesized BMD differences between genotype contrasts
across studies, using ﬁxed and random effects general variance
models [21]. Between-study heterogeneity was assessed by the
chi-square–based Q statistic (Cochran’s Q, considered signiﬁ-
cant for p , 0.10). Random effects models incorporate the
between-study heterogeneity and allow for a different effect in
each population [21]. In the absence of between-study
heterogeneity, ﬁxed and random effects are similar. Unless
reported otherwise, random effects are presented.
For fractures, we used the odds ratio (OR) as the metric of
choice, given the case-control design of some participating
teams. First, we investigated per allele (co-dominant) models
for all fracture outcomes. Recessive and dominant models
were also assessed. In each analysis, ORs were evaluated for
between-study heterogeneity using the Q statistic (considered
signiﬁcant for p , 0.10) and synthesized with ﬁxed (Mantel-
Haenszel) and random (DerSimonian and Laird) effects
methods [21]. Unless stated otherwise, random effects are
presented. Adjusted logistic regression analyses were also
performed stratiﬁed per study and sex (ﬁxed effects) and
considering age, height, weight; hormone replacement ther-
apy, and menopausal status for women; and further adjust-
ment for BMD whenever a potential effect was seen, in order
to examine whether this was explained by differences in BMD.
Analyses were conduced in SPSS 12.0 (SPSS, Chicago,
Illinois, United States), and Meta-Analyst (Joseph Lau, Boston,
Massachusetts, United States). p-Values are two-tailed. Exact
tests for Hardy-Weinberg equilibrium used the GENEPOP
program (http://wbiomed.curtin.edu.au/genepop/) [22]. All
genotype data per participating center and sex were
consistent with Hardy-Weinberg equilibrium.
Results
Clinical Data
Data were gathered on 26,242 individuals (18,405 women),
and 23,926 participants were analyzed (16,936 women) after
selecting only one participant for each FAMOS pedigree
(Table 1). Of the 23,926 participants, data on lumbar spine
BMD, femoral neck BMD, all fractures, and vertebral
fractures were available on 16,739, 17,133, 23,309, and
18,227 participants, respectively. There were 6,067 individu-
als with any fracture, 2,088 with vertebral fractures, 2,407
with incident fractures (412 had incident vertebral fractures),
and 3,743 with low/no-trauma fractures. Standardized data on
Sp1 genotypes were obtained in 20,786 of the 23,926
participants based on sample availability (Table 1).
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Association between COLIA1 Alleles and BMD
The Sp1 polymorphism was associated with BMD both at
the lumbar spine (p ¼ 0.039) and femoral neck (p , 0.001)
using unadjusted ANOVA (Table 2). A comparison of
marginal means showed that TT homozygotes had signiﬁ-
cantly lower BMD values than GT heterozygotes at the lumbar
spine (p ¼ 0.011) and at the femoral neck (p , 0.001), and
lower BMD values than GG homozygotes at the lumbar spine
(p ¼ 0.017) and the femoral neck (p , 0.001). There was no
difference in BMD values at either site between GG
homozygotes and GT heterozygotes (p ¼ 0.80 and p ¼ 0.83,
respectively). The comparison between GG and GT genotype
groups is shown in Figure 1, upper panel. The 95%
conﬁdence intervals (CIs) show that it is possible to exclude
differences between the groups exceeding 7 mg/cm2 at either
skeletal site, which approximates to 0.05 BMD z-score units.
There was no signiﬁcant between-study heterogeneity for this
comparison at either skeletal site (p . 0.3 for both). The
comparison between TT homozygotes and the other geno-
type groups is shown in Figure 1, lower panel. Homozygotes
for the T allele had signiﬁcantly lower BMD than the GG and
GT genotype groups at the lumbar spine: 21 mg/cm2 (95% CI,
1 to 42); and the femoral neck: 25 mg/cm2 (95% CI, 16 to 34).
For the analysis of all study participants, there was some
heterogeneity between studies for BMD values at the lumbar
spine (p ¼ 0.018), but not at the femoral neck (p ¼ 0.6). Sex-
speciﬁc analyses showed similar results for females at the
lumbar spine: 24 mg/cm2 (95% CI, 3 to 46), p ¼ 0.17 for
heterogeneity, and the femoral neck: 26 mg/cm2 (95% CI, 14
to 38), p ¼ 0.9 for heterogeneity. Results for males were not
formally signiﬁcant for the lumbar spine: 18 mg/cm2 (95% CI,
24 to 59) where signiﬁcant heterogeneity was observed
between studies (p ¼ 0.014); but they were signiﬁcant at the
femoral neck: 21 mg/cm2 (95% CI, 1 to 40) and here, there was
no heterogeneity between studies (p ¼ 0.2). Analysis of the
data using ANOVA with adjustment for covariates yielded
similar results (not shown) as the unadjusted analyses.
Association between COLIA1 Alleles and Fracture
There was no signiﬁcant association between the Sp1
polymorphism and fracture overall, whether the data were
analyzed under a co-dominant model (Figure 2A) or recessive
and dominant models of genetic contrasts (Table 3). The tight
95% CI excluded even modest effects, and results were
remarkably similar for both sexes. There was still no evidence
of an association when the analysis focused on incident
fractures: summary OR per allele 1.02 (CI, 0.94 to 1.12) overall;
1.03, (CI, 0.93 to 1.14) in female participants; 1.02 (CI, 0.84 to
1.23) in male participants; or those in whom high-trauma
fractures were excluded: 1.04 (CI, 0.96 to 1.13) overall; 1.06 (CI,
0.97 to 1.15) in femaleparticipants; 1.08 (CI, 0.87 to 1.34) inmale
participants. There was no signiﬁcant heterogeneity between
studies in any analysis with the exception of modest hetero-
geneity in the subgroup ofmale particpants in the co-dominant
(p¼ 0.04 for any fracture) and dominant (p¼ 0.09) models.
For vertebral fractures, there was no evidence for
association in co-dominant (Figure 2B) or dominant models,
whereas there was a non-signiﬁcant trend for association in
the recessive model (Table 3). There was a borderline
signiﬁcant association for incident vertebral fractures under
a co-dominant model (Figure 2C) particularly in females,
where there was a 33% increase in the odds of fracture per
allele (OR 1.33 [CI, 1.00 to 1.77], p ¼ 0.05). Females with the
GT or TT genotype had a 1.40-fold (CI, 1.09 to 1.79) increased
risk for vertebral fracture compared with GG homozygotes (p
¼ 0.009, no between-study heterogeneity). The OR was similar
for TT homozygotes compared with the other genotype
groups, but data were sparse and the result was not
signiﬁcant: OR ¼ 1.33 (CI, 0.69 to 2.58). There was modest
Table 2. Results of Analysis of Variance for BMD
Characteristic Lumbar Spine Femoral Neck
Estimated marginal means
(standard error) of BMD in g/cm2
GG 0.977 (0.002) 0.774 (0.002)
GT 0.976 (0.003) 0.774 (0.002)
TT 0.957 (0.008) 0.750 (0.006)
F 3.257 8.376
Degrees of freedom 2 2
p-Value 0.039 ,0.001
DOI: 10.1371/journal.pmed.0030090.t002
Figure 1. Association between COLIA1 Alleles and BMD
Differences in BMD (in mg/cm2) for the contrasts of GG homozygotes
versus GT heterozygotes are shown in the top panel and those for GG
and GT combined versus TT homozygotes in the bottom panel. For each
study, the point estimates and 95% CIs for the differences in BMD in the
lumbar spine (blue) and femoral neck (green) are shown. The figures are
purposely drawn putting data on the two skeletal sites side by side in
each center for comparison. Summary estimates of the differences and
their 95% CIs are given by random effects models for male (M), female
(F), and all participants (total). Fixed effects estimates are very similar (not
shown). Filled circles represent summary estimates.
DOI: 10.1371/journal.pmed.0030090.g001
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heterogeneity in the co-dominant (p ¼ 0.04) and dominant
(p ¼ 0.01) models for all vertebral fractures in males, but no
heterogeneity in females.
Analyses adjusting for age, height, and weight showed no
association between the Sp1 polymorphism and fracture
overall (summary OR per allele 1.01 [95% CI, 0.95 to 1.07] p¼
0.73), and there was no evidence that this differed across
different ages (p ¼ 0.22 for interaction between the T allele
and age). Adjusting for these factors did not substantially
alter the OR estimates for vertebral fractures or incident
vertebral fractures (vertebral fractures OR per allele ¼ 1.07
[CI, 0.97 to 1.17], p¼0.18; incident vertebral fractures OR per
allele¼1.18 [CI, 0.98 to 1.42], p¼0.088; and incident vertebral
fractures OR for T allele carriers¼ 1.27 [CI, 1.02 to 1.58], p¼
0.033). For female participants, the association remained
signiﬁcant after further adjustment for postmenopausal
status and hormone replacement therapy use (vertebral
fractures OR per allele ¼ 1.10 [CI, 0.98 to 1.23], p ¼ 0.11;
incident vertebral fractures OR ¼ 1.33 [CI, 1.07 to 1.64], p ¼
0.010; and incident vertebral fractures OR for T alleles
carriers ¼ 1.47 [CI, 1.14 to 1.89], p ¼ 0.003). There was no
signiﬁcant interaction with age for any of these effects (p .
0.5 for all interaction terms).
Further adjustment for lumbar spine BMD did not consid-
erably alter any of these effects. In both sexes combined, the
vertebral fractures OR per allele was 1.08 (CI, 0.96 to 1.22), p¼
0.19; the incident vertebral fractures OR per allele was 1.24
(CI, 1.00 to 1.53), p¼0.048; and the incident vertebral fractures
OR for T allele carriers was 1.34 (CI, 1.05 to 1.72), p¼ 0.021.
Discussion
This multicenter collaborative study of COLIA1 Sp1 alleles
in relation to BMD and fractures is, to our knowledge, the
Table 3. Random Effects ORs (95% CIs) for Fracture Risk
Fractures Participants Model
Co-Dominant Dominant Recessive
Any site All 1.01 (0.95–1.08) 1.00 (0.94–1.08) 1.04 (0.87–1.25)
Female 1.01 (0.94–1.08) 1.01 (0.93–1.09) 1.02 (0.83–1.26)
Male 1.05 (0.88–1.25) 1.04 (0.86–1.25) 1.09 (0.74–1.61)
Vertebral All 1.05 (0.92–1.19) 1.06 (0.90–1.25) 1.21 (0.93–1.57)
Female 1.06 (0.93–1.22) 1.06 (0.89–1.26) 1.26 (0.93–1.70)
Male 1.06 (0.79–1.41) 1.11 (0.77–1.61) 1.09 (0.55–2.18)
Fracture risk for the three genetic models tested (co-dominant, dominant, and recessive) is shown.
DOI: 10.1371/journal.pmed.0030090.t003
Figure 2. Association between COLIA1 Alleles and Fractures
OR for fractures in co-dominant models (per T allele) for (A) fracture at any site; (B) vertebral fracture; and (C) incident vertebral fracture. Point estimates
and 95% CIs are shown for the ORs in each study. Summary estimates of the ORs and their 95% CIs (diamonds) are given by random effects models per
gender and for the total database.
DOI: 10.1371/journal.pmed.0030090.g002
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largest ever performed in the ﬁeld of osteoporosis genetics
for a single gene. It indicates that the Sp1 binding site
polymorphism of the COL1A1 gene is associated with BMD at
the lumbar spine and femoral neck with a recessive mode of
inheritance. The effect size was 21 mg/cm2 at the spine and 25
mg/cm2 at the femoral neck, which corresponds to a differ-
ence of about 0.15 BMD z-score units at each site. This differs
from previous studies and their meta-analyses where a co-
dominant effect of the ‘‘T’’ allele has been observed [8,9]. In
this study we found no difference in BMD between GG
homozygotes and GT heterozygotes; only for TT homozygotes
was the documented association with BMD of a similar
magnitude to that reported previously [8,9]. Therefore only a
small fraction of the BMD variance would be explained by
this Sp1 variant, smaller than previously thought. The
association with fracture was also weaker than reported from
previous meta-analyses of smaller studies in which dose-
response effects were observed with doubling or more of the
risk among TT homozygotes [8,9,11], although the associa-
tions in these studies were primarily driven by subjects with
vertebral fractures. In this study we found no association with
fracture overall or when high-impact traumatic fractures had
been excluded. There was a modest association with incident
vertebral fractures, particularly in women, which was
independent of BMD in adjusted analyses. This effect would
translate to an attributable fraction of approximately 10%
for incident vertebral fractures in women. Adjustment for
multiple comparisons might even invalidate the statistical
signiﬁcance of the modest effect on incident vertebral
fractures that we observed. One explanation for the less-
impressive genetic effects documented here is that small
studies in human genome epidemiology may suffer from
selective reporting biases and lack of standardization that can
cause inﬂated effects [3,4,23,24]. Even the latest meta-analysis
of published information on the COLIA1 Sp1 which included
26 studies, comprised fewer than 7,000 participants and only
1,326 patients with fractures [8]. Importantly, only a small
number were TT homozygotes, thereby limiting power to
rigorously assess the association between this relatively rare
genotype and fracture. Moreover, information could not be
standardized across the synthesized published information,
which could have led to erroneous results [25].
A limitation of our study is that many fractures were
ascertained only by clinical history and questionnaires; pre-
vious studies in Europe have indicated 11% false-positive and
7% false-negative reporting rates with such ascertainment [26].
Another limitation is that different inclusion and exclusion
criteria for fracture were used in different cohorts. Neither of
these factors is likely to have caused a large bias however, since
there is no reason to suppose that individuals with a particular
COLIA1 Sp1 genotype would have beenmore or less likely to be
included according to speciﬁc clinical inclusion criteria or
because they reported fractures more accurately. Most of the
previous studies of fractures in relation to COLIA1 Sp1 alleles
have been in hospital clinic–based populations, focusing on
clinical vertebral fracture as the primary outcome. These
studies generally did not include data on prior fractures and
most had no prospective follow-up. Conversely, in this study we
collected all available information on fractures, and we made
efforts to analyze fractures with various standardized sensitivity
analyses to the greatest extent possible.
A major strength of the GENOMOS project is that it
includes over 5-fold more fracture data than all previous
reports combined. Other strengths include the fact that the
databases have been carefully scrutinized centrally and
standardized for deﬁnitions, measurements, and genetic
contrasts. Moreover, large-scale genotyping was performed
for the purposes of this collaborative project. The approach
also eliminates the problem of publication bias within the
conﬁnes of our consortium [27]. Nevertheless, our design is
not totally immune to biases. Measurement error with non-
differential misclassiﬁcation of genotype or phenotype would
tend to diminish the observed ORs. Misclassiﬁcation in
genotyping can seriously affect the results of genetic analysis
[28], but extensive efforts were made to minimize this in the
present study by introduction of strict quality control
processes. Although several different densitometers were
used in the different cohorts, the same instruments were used
in each study center, and all comparisons that focus on
genotype differences did so within, rather than between,
studies. Misclassiﬁcations due to inaccuracies in the clinical
history and documentation of fractures are a more serious
concern and particularly apply to the data on past fractures.
Therefore, the positive association we observed for incident
vertebral fractures may reﬂect to some extent the better
accuracy for determining such fractures by standardized
radiographic criteria and on a prospective basis.
Previous studies have indicated that the COLIA1 Sp1
polymorphism is a functional variant that inﬂuences DNA
protein binding, collagen gene regulation, and bone miner-
alization [10,11]. The data presented here do not negate these
ﬁndings, but rather indicate that these effects do not translate
into an appreciable clinical association with risk of non-
vertebral fractures. Two polymorphisms have been identiﬁed
in the promoter of COLIA1 that are in linkage disequilibrium
with the Sp1 polymorphisms and are associated with BMD
[29,30] and may affect gene transcription [31]. It is possible
that these and other polymorphisms might interact with the
Sp1 variant to inﬂuence bone mass and fracture risk in
speciﬁc populations, but further studies will be needed to
clarify this issue. We cannot exclude the possibility that other
variants may have larger effects than Sp1.
Our results indicate that large-scale studies are needed to
quantify the true effect size of genetic polymorphisms that
have been implicated in the pathogenesis of complex
common diseases such as osteoporosis. Consortia with
standardized large-scale genotyping may place into context
the likely effects of multigenetic inheritance.
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Patient Summary
Background. Osteoporosis is a condition characterized by subtle
deterioration of bone tissue leading to decreased bone mass and to
bone fragility. Doctors often measure a person’s bone mineral density to
see if he or she has osteoporosis. The major causes of osteoporosis are
poor building of bone mass during adolescence and accelerated bone
loss after middle age, especially in women (as a result of menopause).
Both bone building and bone loss are regulated by genetic and
environmental factors. Osteoporosis is thought to be a ‘‘complex
disease,’’ with variations in a number of different genes and environ-
mental factors affecting an individual’s risk. Researchers have identified a
number of genes that are good candidates to play a role in osteoporosis.
One such gene is called COL1A1. It contains the genetic information to
make collagen alpha, a major component of bone and cartilage.
Different forms of the COL1A1 gene have been identified. (Most, if not all
human genes, exist in different forms.) One relatively common variant,
which might affect bone quality based on experiments in human bone
tissue, has been studied intensely in the past. At a particular position in
the gene, two versions exist: the more common G version and the T
version. Because humans have two copies of the COL1A1 gene, they can
have two G versions, one G and one T version, or two T versions.
Why Was This Study Done? Several previous studies had examined a
possible association between the T version of the COL1A1 gene and low
bone mineral density and fractures, and a number of the studies had
found such a link. As a consequence, some scientists have suggested
that people should get genetic tests for the high-risk variant, and that
those who have it should make sure to get enough calcium and do
weight-bearing exercises, ideally during the bone-acquisition phase in
adolescence. Other scientists have warned that the evidence that links
the T version to a higher risk for osteoporosis is not strong enough to
support such action. This study was done to find a conclusive answer.
What Did the Researchers Do and What Did They Find? The authors
of this study work in universities and hospitals all over Europe. They have
joined forces to do what is likely the largest test for a link between a
specific genetic variant and osteoporosis. Each group collected data
from patients whom they recruited and examined locally, but they all
agreed on rigorous common standards upfront and made sure that
those were upheld, so that in the end they were able to combine the
data from all the patients. They collected data on fractures, measured
bone mineral density, and determined whether an individual had the GG,
GT, or TT combination of their two COL1A1 copies for more than 20,000
participants in the study. They found a modest association between the
TT version and lower bone mineral density at the femoral neck and the
lumbar spine. They did not find an overall link between the TT
combination and fractures. However, they did find a weak association
between the T version and vertebral fractures in women.
What Does This Mean? Overall, the effects they saw were more
moderate than most of the earlier studies. These effects explained only a
small part of the differences in bone mineral densities and fractures
between the participants. The researchers found no difference in bone
mineral density between people who have one copy of the T variant and
those who have two G variants (and only approximately 4% of people
have two copies of the T variant). Regarding the fracture association, the
researchers estimate that having the T variant would explain at most
10% of the risk of vertebral fractures for women. From these results, it
seems clear that genetic testing for this particular variant in isolation
would be premature. Researchers need to look at other genes (and
possibly other variants in the COL1A1 gene) before they can predict a
substantial fraction of an individual’s genetic risk for osteoporosis.
Where Can I Find More Information Online? The following Web sites
provide information on osteoporosis.
UK National Osteoporosis Society:
http://www.nos.org.uk/public.asp
MedlinePlus pages for osteoporosis:
http://www.nlm.nih.gov/medlineplus/osteoporosis.html
Patient information pages from the Endocrine Society:
http://www.hormone.org/learn/osteoporosis.html
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